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Abstract
Background: Sugar cane policosanols (SCP) have been shown to exert cholesterol-modulating
properties in various studies conducted in Cuba by substantially reducing cholesterol synthesis.
Independent research examining changes in cholesterol kinetics in response to SCP is limited to
few studies, none of which was able to replicate findings of the original research. Moreover, no data
are available on the effect of SCP on cholesterol absorption to date. The present study was
undertaken to determine effects on cholesterol kinetics, namely synthesis and absorption, within
hypercholesterolemic individuals consuming a SCP treatment. Twenty-one otherwise healthy
hypercholesterolemic subjects participated in a randomized double-blind crossover study where
they received 10 mg/day of policosanols or a placebo incorporated in margarine as an evening snack
for a period of 28 days. The last week of the study phase, subjects were given 13C labelled
cholesterol and deuterated water for the measurement of cholesterol absorption and synthesis
respectively. Blood was collected on the first two and last five days of the trial. Cholesterol
absorption and synthesis were determined by measuring red cell cholesterol 13C and deuterium
enrichment, respectively.
Results: There was no significant change in LDL cholesterol levels as compared to control. In
addition, the area under the curve for red cell cholesterol 13C enrichment across 96 hours was not
significantly different in the SCP group as compared to control. Similarly, no difference was
observed in the fractional rate of cholesterol synthesis over the period of 24 hours between the
two treatment groups.
Conclusion: The findings of the present study fail to support previous research concerning
efficacy and mechanism of action for policosanols.
Introduction
The most commonly used cholesterol-lowering agents
contribute to the prevention of cardiovascular disease
through their action on cholesterol metabolism, namely
absorption and synthesis [1-3]. Until recently, sugar cane
policosanols (SCP) have been extensively researched
within a single jurisdiction in Cuba, purporting efficacy in
suppressing cholesterol biosynthesis, resulting in up to
30% reductions in plasma low density lipoprotein choles-
terol (LDL-C). SCP supplementation studies have estab-
lished that its cholesterol-lowering effect, mainly
mediated by a decrease in serum LDL-C levels, is due to
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the inhibition of hepatic cholesterol synthesis and stimu-
lation of receptor-mediated LDL uptake by the liver [4-7].
Cholesterol synthesis was assessed in vitro by measuring
the enrichment of tritiated water into human fibroblasts
[7] and animals in vivo [6]. In these studies, synthesis was
seen to decrease as a result of SCP treatment.
Unlike statins which inhibit cholesterol biosynthesis by
directly affecting the rate-limiting enzyme HMG-CoA
reductase, SCP seems to have a different, more complex
mechanism of action [5]. In human cultured fibroblasts
[5,7] using 14C acetate and 14C mevalonate as tracers, SCP
interfered with the cholesterol biosynthesis pathway at a
step between acetate and mevalonate production. Since
decreased cholesterol biosynthesis is associated with
increased LDL-receptor expression in hepatocytes [8,9],
SCP effects on serum LDL-C can be suggested as originat-
ing from increased LDL- binding, uptake or degradation,
as demonstrated in studies measuring radiolabeled LDL
on the surface of human fibroblasts [5].
Although studies conducted in Cuba agree internally con-
cerning effects of SCP on cholesterol biosynthesis, only
two studies have been conducted outside the Cuban juris-
diction. The first of these two studies, an in vitro trial, con-
firmed findings from the original research [10]. The
second trial, conducted on animals, presented conflicting
outcomes [11]. Indeed, the latter contributes to the con-
troversy associated with policosanols, showing that cho-
lesterol biosynthesis was not affected in hamsters fed SCP
[11]. We thus recognize that the lipid-lowering mecha-
nism of SCP is not fully understood, especially since other
cholesterol-lowering mechanisms such as inhibition of
cholesterol intestinal absorption have not been investi-
gated.
The objective of the present study was therefore to exam-
ine the effect of SCP in vivo on cholesterol synthesis and
absorption in hypercholesterolemic individuals. We
hypothesized that there would be no significant change in
cholesterol synthesis and/or absorption as a result of SCP
supplementation for 28 days.
Subjects and methods
Subjects and treatments
Otherwise healthy hypercholesterolemic men and post-
menopausal women (n = 21) age 40 to 80 years, BMI
ranging between 23 and 30 kg/m2 were recruited for the
clinical trial. Volunteers were asked to visit the research
unit for two screenings including a blood draw to deter-
mine their lipid profile and other health parameters as
well as a medical exam. Subjects accepted in the study had
plasma LDL-C levels ranging from 3.0 mmol/l to 5.0
mmol/l and triacylglycerol levels below 4.0 mmol/l at
screening.
Exclusion criteria included history of recent or chronic use
of oral hypolipidemic therapy, chronic use of insulin, sys-
temic antibodies, corticosteroids, androgens or pheny-
toin. Subjects were also excluded if they had experienced
a myocardial infarction, coronary artery bypass or other
major surgical procedures within the last six months, or
reported recent onset of angina, congestive heart failure,
inflammatory bowel disease, pancreatitis, or hypothy-
roidism. Significant pre-existing diseases including can-
cer, chronic use of laxatives as well as smoking or
consumption of more than 2 drinks per day were also
considered to be part of the exclusion criteria. Before
enrolment, subjects were asked to sign a consent form
outlining the details of the trial. All procedures included
in the protocol were approved by the ethics committee of
the medical faculty of McGill University.
Policosanols derived from sugar cane wax (Lipex, Dalmer
Laboratories, La Havana, Cuba) were purchased in the
form of 5 mg pills which were crushed and incorporated
into margarine. The composition of the SCP treatment
was: 65.6% octacosanol, 13.4% triacontanol and 4.5%
hexacosanol [12]. The daily dose of treatment provided
10 mg of policosanols mixed with 10 g of margarine
(Becel, Canada) and was served on a slice of bread. [3,4-
13C] cholesterol and deuterium oxide (99.8 atom percent
excess) were obtained from CDN isotopes (Montreal,
Canada). [3,4- 13C] cholesterol was incorporated in mar-
garine (Becel, Canada) by thorough mixing at a concen-
tration of 7.5 mg/g margarine.
Protocol
The study was designed as a randomized double-blind
crossover where subjects were assigned to receive the SCP
or placebo margarines as a daily evening snack for a
period of 28 days. The two treatment phases were sepa-
rated by a wash out period of the same duration. Study
participants were asked to visit the clinic everyday and
consume the snacks under staff supervision at the Mary
Emily Clinical Research Centre, in order to ensure abso-
lute compliance. Subjects were requested to maintain
their habitual diet and physical activity patterns through-
out the study and to abstain from alcohol throughout the
treatment phases. Caffeinated drinks were restricted to
one cup per day and subjects were offered caffeine-free
beverages with their snacks. At the beginning and end of
each phase, a three-day 24-hour recall was recorded for
each subject to ensure that there were no substantial
changes in their dietary habits within and between the
two phases. Body weights were recorded daily in order to
monitor weight fluctuations throughout the study period.
On day 25, subjects were administered 10 g of margarine
spread on a slice of bread providing a dose of 75 mg of
[3,4- 13C] cholesterol. Blood was collected before isotopeLipids in Health and Disease 2008, 7:17 http://www.lipidworld.com/content/7/1/17
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ingestion (hour 0) and 24, 48, 72 and 96 hours after
ingestion in order to measure cholesterol absorption. On
day 28, subjects were asked to drink a dose of 0.7 g deute-
rium oxide/kg body water (60% of body weight recorded
during the last 5 days). Blood was collected before isotope
administration (hour 0) and at hour 24 for cholesterol
biosynthesis measurements.
Nutrient composition of the diet
Subjects' food intake for the previous day was recorded at
the start and end of each intervention phase. Subjects were
advised to write the food items and the exact quantity after
each meal to reduce the memory bias during the interview
the next day. They were provided with portion models,
including cups, plates, bowls, spoons to help them report
portions more accurately. Nutrient composition of food
items was analyzed using Food Processor version 1.0 and
the average macronutrient, cholesterol and dietary fibre
content of the diet over three days was computed at the
start and end of the phase. Macronutrient intake was then
expressed as percent energy.
Determination of cholesterol absorption
Blood was collected by venipuncture into 10 ml EDTA
tubes. Red blood cells (RBCs) were separated from plasma
by centrifugation at 15,000 rpm for 30 minutes and stored
at -80°C for further analysis. Cholesterol absorption was
measured using the single-stable isotope-labeled choles-
terol tracer approach which was validated against the
commonly used dual stable-isotope ratio method and
shown to be reliable in the determination of cholesterol
intestinal absorption [13]. The lipid fraction of RBCs was
isolated using the modified Folch extraction procedure
[14]. Lipid extracts were analyzed using gas chromatogra-
phy isotope ratio mass spectromety (GC-IRMS, Ther-
moFinnigan, Bremen, Germany) where samples were run
through a GC unit, a combustion reactor and a mass spec-
trometer. Briefly, lipids were separated by gas chromatog-
raphy using a SAC-5 sterol column (Supelco, Milton,
Ontario) and isolated cholesterol was directed to the com-
bustion reactor to release CO2 into the MS where 13C
enrichment of CO2 (δ 13CO2/12CO2) was determined rel-
ative to the reference gas and expressed relative to the
international standard Vienna Pee Dee Belemita (V-PDB)
limestone. Enrichments were measured for each of hours
0, 24, 48, 72 and 96 and the area under the curve (AUC)
was used to compare cholesterol absorption in the SCP
and control groups.
Determination of cholesterol biosynthesis
Blood was collected on day 28 (hour 0) and 29 (hour 24)
and lipid extraction performed using the same methods
mentioned for the determination of cholesterol absorp-
tion. Cholesterol synthesis was assessed by measuring the
rate of deuterium incorporation from body water into
RBC membrane free cholesterol over 24 hours. Lipid
extracts from RBCs were separated using GC and isolated
cholesterol was introduced into a pyrolysis reactor to
release H2 gas. Plasma water samples were run through a
high temperature conversion elemental analyzer (TC-EA).
Deuterium enrichments for both RBCs and plasma water
were measured by IRMS relative to the reference gas. Nor-
malization to Vienna standard mean ocean water (V-
SMOW) was performed using a regression equation
between the online and offline method (as mentioned
above) with data from the offline method expressed rela-
tive to V-SMOW. The fractional rate of synthesis (FSR) for
cholesterol was then calculated using the following equa-
tion:
FSR (pools/day) = (δ C/δ PW) × 0.478
Where:
δ C = difference in deuterium enrichment between hour 0
and hour 24 for cholesterol
δ PW = difference in deuterium enrichment between hour
0 and hour 24 for plasma water
0.478 = ratio of labeled H atoms replaced by deuterium
during in vivo biosynthesis
Statistical analysis
The sample size (n = 21) for the clinical trial was calcu-
lated to provide an 80% probability of detecting an antic-
ipated difference in parameters tested of 20%, using a
coefficient of variation of 15–20%. Effects of SCP treat-
ment on cholesterol absorption and synthesis were com-
pared to control using a one-way ANCOVA for crossover
models. The effect of sequence, treatment, period, subject
and gender were included in the model. Macronutrient,
cholesterol and dietary fibre intakes were compared at the
start and end of each phase and between the two interven-
tions using student t-tests. Multiple regressions between
cholesterol kinetic parameters (AUC and FSR) and nutri-
ent intake as well as age, BMI and LDL levels were per-
formed to identify potential covariates. The model was
subsequently adjusted for those covariates. Statistical sig-
nificance was set at p < 0.05.
Results
Compliance and drop-out rate
Twenty-two subjects were recruited to take part in the clin-
ical trial and twenty-one successfully completed the study.
Baseline characteristics of subjects are presented in Table
1. The SCP and placebo margarines were well-tolerated.
No serious adverse effects were reported throughout the
trial with the exception of four subjects reporting gastroin-
testinal discomfort and more frequent bowel movements.Lipids in Health and Disease 2008, 7:17 http://www.lipidworld.com/content/7/1/17
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Two of these were in the SCP group while the other two
received the control intervention. Body weights remained
stable throughout the study periods and blood biochem-
istry and hematology were within normal ranges.
Plasma lipid levels
Plasma lipid levels were measured and results were pub-
lished in previous work [15]. Briefly, no significant differ-
ences were observed between SCP treatment and control
groups in plasma total, LDL, HDL and triacylglycerol lev-
els. These outcomes were observed both with endpoint
values and percent changes in blood lipids.
Dietary intake throughout the study period
Macronutrient, cholesterol and dietary fiber intakes
throughout the study are presented in Table 2. Values are
presented as mean ± SEM. Nutrient content and composi-
tion of the subjects' diet were similar at the beginning and
end of the two intervention phases. Average caloric and
nutrient intakes throughout the SCP intervention were
2005 ± 127 calories, 35.7% from fat (10.9% saturated),
15.1% from proteins and 51.1% from carbohydrates. In
comparison, subjects consumed 2109 ± 127 calories,
35.5% from fat (11.0% saturated), 15.3% from proteins
and 50.4% from carbohydrates. Subjects' dietary choles-
terol and fibre intakes were assessed as 141.3 ± 12.7 mg/
day and 19.9 ± 1.6 g/day respectively during the SCP inter-
vention. Subjects in the control intervention had choles-
terol and dietary fibre intakes of 120.5 ± 12.7 mg/day and
20.0 ± 1.6 g/day respectively. No differences between
groups were noted for all nutrients demonstrating that
study participants maintained their dietary habits
throughout the study period.
Cholesterol absorption as a result of SCP supplementation
Cholesterol 13 C enrichments in red blood cells at different
time points are illustrated in Figure 1. Values are pre-
sented as mean ± SEM. At hour 24, recorded enrichments
versus V-PDB were (p = 0.0098) -16.4 ± 0.43 ‰ and -16.0
± 0.43 ‰ in the SCP and control groups, respectively. At
hour 48, enrichment values in the two groups were (p =
0.0221) -15.9 ± 0.42 ‰ and -15.3 ± 0.43 ‰ respectively.
At other time points, no significant difference was
observed between SCP and control treatments. When
enrichment values were calculated as the difference from
baseline (Figure 2), SCP supplementation showed no sig-
nificant effect on this parameter at all time points. Choles-
terol absorption rate was determined as the area under the
13C enrichment curve. Calculated AUC for SCP and con-
trol is presented in Figure 1. Results show that in the SCP
Table 1: Baseline characteristics of subjects (n = 21)
Variable Males (n = 12) Females (n = 9) All (n = 21)
Age (y) 54.0 ± 2.9 a 60.1 ± 2.6a 57.8 ± 2.1
Weight (kg) 84.8 ± 4.9 a 71.1 ± 3.8 b 76.3 ± 3.2
BMI (kg/m2) 26.9 ± 1.0 a 26.3 ± 0.8 a 26.5 ± 0.6
Total cholesterol (mmol/l) 5.4 ± 0.4 a 6.09 ± 0.3 a 5.8 ± 0.2
LDL- cholesterol (mmol/l) 3.5 ± 0.3 a 3.8 ± 0.3 a 3.7 ± 0.2
HDL- cholesterol (mmol/l) 1.2 ± 0.1 a 1.6 ± 0.1 b 1.4 ± 0.09
Triacylglycerols (mmol/l) 1.5 ± 0.4 a 1.7 ± 0.3 a 1.6 ± 0.2
Values with different superscript letters are statistically different at p < 0.05.
Male/Female ratio = 1.3
Table 2: Nutrient composition of subjects' diet throughout the study period (n = 21)
Control SCP
Average intake/day Start End Start End
Energy (Kcal) 2126.2 ± 152.0 2084.5 ± 148.3 1900.0 ± 130.2 2109.8 ± 130.2
Fat (g) 87.03 ± 6.92 80.41 ± 6.76 72.71 ± 5.05 83.77 ± 5.05
% energy from fat 37.15 ± 1.66 34.26 ± 1.62 35.33 ± 1.41 36.15 ± 1.41
Saturated fat (g) 26.37 ± 2.32 25.09 ± 2.26 22.97 ± 1.94 24.84 ± 1.94
Energy from saturated fat (%) 11.33 ± 0.69 10.84 ± 0.67 11.10 ± 0.66 10.70 ± 0.66
Proteins (g) 75.90 ± 6.46 82.47 ± 6.31 68.52 ± 4.30 79.23 ± 4.30
Energy from proteins (%) 14.59 ± 0.80 15.91 ± 0.78 14.68 ± 0.68 15.47 ± 0.68
Carbohydrates (g) 270.29 ± 22.3 262.59 ± 21.7 252.82 ± 22.4 269.33 ± 22.4
Energy from carbohydrates (%) 50.28 ± 1.65 50.36 ± 1.61 52.11 ± 1.77 50.11 ± 1.77
Cholesterol (mg) 261.14 ± 32.8 249.95 ± 32.0 249.64 ± 33.9 304.50 ± 33.9
Cholesterol (mg/1000 Kcal) 123.95 ± 11.1 116.70 ± 10.8 130.84 ± 7.21 151.65 ± 17.2
Dietary fibre (g) 20.98 ± 1.77 18.82 ± 1.73 19.34 ± 1.79 20.71 ± 1.79Lipids in Health and Disease 2008, 7:17 http://www.lipidworld.com/content/7/1/17
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group, cholesterol absorption was lower than control by
7.2%, although the difference did not reach significance
(p = 0.10). The fixed effect of gender on cholesterol
absorption was significant (p = 0.03), and was manifested
by a mean AUC of 513 in female subjects as compared to
362 in males. The effect of diet as determined by multiple
regressions was significant (p = 0.02) for caloric intake
which was included in the model as a covariate. Adjusted
AUC means in the two interventions were not signifi-
cantly different (p = 0.1).
Cholesterol synthesis as a result of SCP supplementation
Cholesterol fractional rate of synthesis was (mean ± SEM)
0.0169 ± 0.001 pools/day and 0.0170 ± 0.001 pools/day
in the SCP and control groups respectively with no signif-
icant difference between the effects of the two interven-
tions. Results show no difference in FSR between males
and females (p = 0.65). Daily intake of energy (p = 0.03)
and energy from saturated fat (p = 0.03) had significant
effects on FSR and were included in the model as covari-
ates. The effect of SCP treatment remained non-significant
after adjustment for covariates.
Discussion
The present study is the first human clinical trial to assess
the effect of SCP on cholesterol intestinal absorption and
biosynthesis using cholesterol isotope labeling methodol-
ogies. Our results do not agree with the larger body of evi-
dence showing that SCP interfere with the biosynthetic
pathway of cholesterol in the liver decreasing its levels in
the blood in either animals [4,6] and humans [5,16,17].
The research group originating these claims used rats and
rabbits treated with doses of SCP and measured the rate of
incorporation of 3H from tritium oxide into hepatic ster-
ols [4,6]. The authors of both animal trials report signifi-
cant reductions of tritium incorporation of up to 50% as
a result of SCP administration to the animals concluding
that SCP reduced the rate of cholesterol biosynthesis.
However, these findings were challenged by more recent
animal data [11] using deuterium incorporation into red
blood cells in a hamster model treated with SCP and
showing no effect on cholesterol biosynthesis as a result
of SCP administration. In another trial from the same
authors, different doses of policosanols were seen to
increase the rate of cholesterol biosynthesis in the animals
[18]. In humans, no studies are available that examine the
effect of SCP on cholesterol metabolism in vivo. Rather, in
vitro experiments were conducted on human fibroblasts
[5,16,17] and hepatoma cells [10] incubated with increas-
ing doses of policosanols and subjected to the addition of
14C-acetate and 14C-mevalonate. A clear dose-dependant
reduction was observed in the incorporation of 14C-ace-
tate into cellular cholesterol as a result of SCP treatment
[5,10]. In fact, as policosanol concentration increased,
radioactivity incorporated from acetate, but not from
mevalonate, decreased significantly reaching an inhibi-
tion of 30% [10] and 49.7% [5] at the 25 μg/ml and 50
μg/ml dose respectively. The authors concluded that poli-
cosanols interfered in the cholesterol synthetic pathway at
a step between acetate and mevalonate production.
While the evidence from these experiments seems com-
pelling, the method of choice can be strongly criticized
when applied to metabolically active compounds, in this
case policosanols. In a cellular medium, policosanols are
metabolized into their corresponding acids and subse-
quently enter the beta-oxidation pathway [19]. A dilution
effect can be suggested in this case whereby policosanol-
derived acetate contributes to reducing the ratio of 14C/
12C-acetate in the medium, resulting in an artificial inhib-
Difference in 13C enrichment between time points and hour  0 as a result of isotope administration in SCP and control  groups (n = 21) Figure 2
Difference in 13C enrichment between time points 
and hour 0 as a result of isotope administration in 
SCP and control groups (n = 21). Black diamond: sugar 
cane policosanols, grey diamond: placebo. No significant dif-





























13C enrichment of RBCs after isotope administration in SCP  and control groups (n = 21) Figure 1
13C enrichment of RBCs after isotope administration 
in SCP and control groups (n = 21). Black diamond: 
sugar cane policosanols, grey diamond: placebo. AUC SCP = 
421.91; AUCcontrol = 454.55. No significant difference 
between the two intervention groups. n = 21.
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itory effect of policosanols on cholesterol synthesis. This
hypothesis would explain the absence of effect when
using 14C-mevalonate which is not a product of beta oxi-
dation of policosanols. The present study overcomes the
aforementioned limitations by examining the effect of
SCP in vivo, using deuterium incorporation into red blood
cell cholesterol. This method has been used in numerous
human trials and was shown to be an accurate, reliable
and safe method for the determination of cholesterol syn-
thesis [20-23].
The study was designed so that subject compliance to the
protocol was ensured by close supervision from the clini-
cal staff and that the SCP treatment was the one used in
earlier original research at a dose previously shown to
decrease cholesterol levels in humans [24-26]. Moreover,
the treatment was administered in the evening because
cholesterol synthesis has been shown to reach maximal
values at night [27,28]. It remains that no significance was
recorded as to the effect of SCP on cholesterol biosynthe-
sis which explains the inefficacy of the treatment in
improving the lipid profile of study participants and sup-
ports the growing body of evidence originating from inde-
pendent research groups reporting no change in blood
lipids [15,29-33].
The poor absorption of SCP in the gut and the increase in
synthesis as a result of treatment seen in the Wang et al
study [18] generated the interest in determining the effect
of SCP on cholesterol absorption in the present study. A
mechanism of action similar to that of plant sterols
whereby SCP would compete with cholesterol in the gut
[34], decreasing its absorption and slightly increasing its
synthesis, was suggested as a hypothesis in this study.
Although absolute 13C enrichments were significantly
lower than control in the SCP group at hour 24 and 48,
the effect disappeared when levels were adjusted for base-
line. Moreover, the AUC for 13C enrichments, a better
marker for cholesterol absorption was not significantly
different across intervention groups. Results thus show no
effect of SCP on cholesterol absorption in the gut, and this
independently of the subjects' dietary intake.
Earlier human efficacy studies on SCP did not control die-
tary intake of participants [35-38]. Subjects were given
dietary advice and asked to follow an NCEP step I diet. In
the present study, subjects were asked to maintain a stable
diet and food intake was recorded thoroughly in order to
ensure there were no nutritional differences between the
two intervention groups. Results show that nutrient intake
remained stable throughout the study phases and
between the two groups allowing us to rule out the possi-
bility of a confounding effect of food. Nutrient analyses
also showed that caloric intake was negatively related to
cholesterol absorption and positively to synthesis. A sim-
ilar relationship has been reported previously in trials
looking at caloric restriction, weight loss and their effect
on cholesterol synthesis [39-41], however, few studies
have examined the impact of caloric restriction on choles-
terol absorption. Although two studies including diabetic
subjects observed a negative relationship between choles-
terol absorption and caloric intake [42,43], a more recent
trial has shown no significant effect of caloric restriction
or weight loss on cholesterol absorption [41]. Percent
energy from saturated fat in the subjects' diet was nega-
tively related to cholesterol synthesis across intervention
groups. Saturated fats have long been associated with
increased blood cholesterol [44,45], however, their effect
on cholesterol metabolism depends on other factors such
as concurrent intake of dietary cholesterol and the ratio of
polyunsaturated to saturated fats [46]. Since dietary intake
and fatty acid composition were not controlled in this
study, the relationship between saturated fat and choles-
terol metabolism remains inconclusive. When energy
intake and percent saturated fat were adjusted for in the
model as covariates, the SCP treatment remained ineffec-
tive in altering parameters of cholesterol metabolism.
Considering previous independent findings on the ineffi-
cacy of SCP [15,29,32,47] as well as its poor absorption
[12,19], the claim that SCP inhibits cholesterol synthesis
by an indirect effect on HMG-CoA reductase in peroxi-
somes is further refuted by the outcomes of the present
study. We therefore conclude that the natural lipid-lower-
ing agent does not alter cholesterol intestinal absorption
and/or hepatic biosynthesis.
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